BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Calvet X. Dealing with uncertainty in the treatment of Helicobacter pylori. Ther Adv Chronic Dis 2018;9:93-102. [PMID: 29623181 DOI: 10.1177/2040622318758240] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Nyssen OP, Espada M, Gisbert JP. Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Front Microbiol 2022;13:913436. [DOI: 10.3389/fmicb.2022.913436] [Reference Citation Analysis]
2 Sánchez-Alonzo K, Belmar L, Parra-Sepúlveda C, Bernasconi H, Campos VL, Smith CT, Sáez K, García-Cancino A. Antibiotics as a Stressing Factor Triggering the Harboring of Helicobacter pylori J99 within Candida albicans ATCC10231. Pathogens 2021;10:382. [PMID: 33806815 DOI: 10.3390/pathogens10030382] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Gisbert JP. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? Therap Adv Gastroenterol. 2020;13:1756284820968736. [PMID: 33240392 DOI: 10.1177/1756284820968736] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
4 Zhao Y, Ren M, Wang X, Lu G, Lu X, Zhang D, He S. Telephone-Based Reeducation of Drug Administration for Helicobacterpylori Eradication: A Multicenter Randomized Controlled Study. Gastroenterol Res Pract 2020;2020:8972473. [PMID: 32802048 DOI: 10.1155/2020/8972473] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Olmedo L, Azagra R, Aguyé A, Pascual M, Calvet X, Gené E. High Effectiveness of a 14-Day Concomitant Therapy for Helicobacter pylori Treatment in Primary Care. An Observational Multicenter Study. J Clin Med 2020;9:E2410. [PMID: 32731455 DOI: 10.3390/jcm9082410] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Hanafy AS, Seleem WM. Refractory Helicobacter pylori gastritis: The hidden predictors of resistance. Journal of Global Antimicrobial Resistance 2019;19:194-200. [DOI: 10.1016/j.jgar.2019.05.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Ciccaglione AF, Cellini L, Marzio L. Pylera® plus ranitidine vs Pylera® plus esomeprazole in first‐line treatment of Helicobacter pylori infection: Two pilot studies. Helicobacter 2019;24. [DOI: 10.1111/hel.12606] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
8 Baylina M, Muñoz N, Sánchez-Delgado J, López-Góngora S, Calvet X, Puig I. Systematic review: Would susceptibility-guided treatment achieve acceptable cure rates for second-line Helicobacter pylori therapy as currently practiced? Helicobacter 2019;24:e12584. [PMID: 30990575 DOI: 10.1111/hel.12584] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]